Scarica l'app Stockscreener
469.34
1.84%
-8.79
Dopo l'orario di chiusura:
470.28
0.94
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Vertex Pharmaceuticals (VRTX)'s IgA Nephropathy Win Means For Its Next Major Franchise Potential - simplywall.st
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup - ChartMill
2 Factors to Consider Investing in VRTX and 1 Reason to Remain Careful - Bitget
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals (VRTX) Pricing In Too Much Optimism After Recent Share Gains? - simplywall.st
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Pharmaceuticals (VRTX) Sees Target Price Raised by Truist Securities | VRTX Stock News - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Acquires 14,706 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CreativeOne Wealth LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma (NASDAQ:VRTX) Market Focus Builds Across Nasdaq Index - Kalkine Media
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo! Finance Canada
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Vertex Pharmaceuticals Shares Sold by Schroder Investment Management - National Today
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Schroder Investment Management Group - MarketBeat
Van ECK Associates Corp Has $58.38 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex preps FDA filing for IgAN drug after phase 3 readout - pharmaphorum
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Richard Bernstein Advisors LLC Sells 4,059 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
DE Burlo Group Inc. Sells 43,740 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise - simplywall.st
Blair William & Co. IL Reduces Vertex Pharmaceuticals Stake - National Today
Bank of Montreal Boosts Vertex Pharmaceuticals Holdings by 15.5% - National Today
Vertex Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating - Investor's Business Daily
Bank of Montreal Can Has $164.28 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Narrow-Moat Vertex's Positive Data for Povetacicept Support Diversification Beyond Core CF Franchise - Morningstar
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Yahoo Finance
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug - Investor's Business Daily
Vertex Pharmaceuticals Stock Jumps with Positive Drug Pipeline News - timothysykes.com
Vertex Pharmaceuticals Hits Milestone with Povetacicept Data, Shares Surge - StocksToTrade
These Stocks Are Today’s Movers: BioNTech, NIO, Centene, Vertex, Paramount, Rivian, Occidental, and More - Barron's
Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. - Barron's
Vertex Pharmaceuticals (VRTX) Receives Rating Update and Price T - GuruFocus
Key facts: Vertex Pharmaceuticals reports positive trial results; firms raise price targets - TradingView
Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today - TipRanks
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition - MedCity News
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send? - TradingKey
Vertex Pharma Stock Rises on IgA Nephropathy Drug Trial Success | 2026News and Statistics - IndexBox
Vertex to seek approval of IgAN drug after Phase III success - Clinical Trials Arena
Vertex Pharmaceuticals Soars on Promising Phase 3 Trial Results for Povetacicept - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley - MarketBeat
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study - Finviz
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results - Investopedia
Oil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday? - Benzinga
Vertex Pharmaceuticals (VRTX) Rating Maintained, Price Target Ra - GuruFocus
Vertex filing BLA for ‘best-in-class’ IgAN drug on Rainier win - bioworld.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $598.00 Price Target at Bank of America - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher Following Analyst Upgrade - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $585.00 at Citigroup - MarketBeat
Vertex Pharmaceuticals (VRTX) Receives New Analyst Price Target Increase | VRTX Stock News - GuruFocus
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals - Benzinga
Truist raises Vertex stock price target on positive trial data - Investing.com
Jefferies Initiates Coverage on Vertex Pharmaceuticals (VRTX) wi - GuruFocus
Truist Securities Adjusts Price Target on Vertex Pharmaceuticals to $525 From $490, Maintains Buy Rating - marketscreener.com
Vertex Rises as Kidney Drug Meets Goal in Late-Stage Trial - Bloomberg.com
Vertex Ratchets Up Competition In IgAN With Povetacicept Phase III Win - Citeline News & Insights
H.C. Wainwright raises Vertex stock price target on renal data - Investing.com
Vertex Pharmaceuticals stock surges 6% on kidney drug trial win By Investing.com - Investing.com Canada
Why Is Vertex Pharmaceuticals Stock Soaring Tuesday?Vertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Jefferies Financial Group - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $600.00 at Oppenheimer - MarketBeat
Vertex's $4.9B bet nears payoff with important milestone - NBC Boston
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):